跳至主要内容
临床试验/DRKS00026171
DRKS00026171招募中不适用

Prospective observational study to investigate the long-term course of MR-guided percutaneous tumor ablation of primary or secondary liver or kidney tumors

niversitätsklinikum Tübingen0 个研究点目标入组 300 人开始时间: 2021年8月23日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 100 Years(—)
性别
All

入选标准

  • Patients who have clinically indicated tumor ablation for primary or secondary liver or kidney tumors.
  • - The indication for percutaneous tumor ablation takes place in an interdisciplinarytumor conference.
  • - Completion of the age of 18 and the patient's legal capacity to give consent.
  • - Concomitant diseases or adjuvant chemotherapy or previous therapy using transarterial chemotherapy or other ablation procedures do not constitute exclusion criteria for participation in the study.

排除标准

  • - Missing or incomplete declaration of consent from the patient.
  • - Minor patients.
  • - Pregnant / breastfeeding women.
  • - Patients incapable of giving consent.

研究者

发起方
niversitätsklinikum Tübingen

相似试验